Mycophenolate

Mycophenolate is an immunosupressant, first isolated in 1898 from Penicillium stoloniferum. Mycophenolate is a reversible inhibitor of inosine monophosphate dehydrogenase and thus inhibits purine synthesis, with potent cytostatic effects on both T-and B-lymphocytes. Mycophenolate is used in combination with other immunosupressants, for the treatment and prevention of graft rejection and in auto-immune or immune-mediate inflammatory disease. it was approved by the FDA in May 3, 1995, for prevention of alograft rejection.

Brands
MYCOLATE IMUXGEN MYFORTIC MYFORTIC CELLCEPT MYGRAF SALVER CYCOPIN SUPRIMUN MYCOPHENOL ORGOCEPT MYPHENO MY-REPT
Adult Dose
Dose: 1 g
Single Dose: 1 (1)
Frequency: 12 hourly
Route: PO
Instructions: Starting within 72 hrs of transplantation.
Neonatal
Paedriatic
Characteristics
Mycophenolate Mofetil is the derivative of Mycophenolate. It is of Synthetic origin and belongs to Mycophenolie acid. It belongs to Immunosuppressant Agent pharmacological group.The Molecular Weight of Mycophenolate is 433.50.
Contraindications
Mycophenolate
Effects
The severe or irreversible adverse effects of Mycophenolate, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Leucopenia, Bone marrow depression, Hyperglycemia, Hypertension, Hematuria, Tremors, Hyperglycemia, Anemia, Anemia, Disturbances of electrolyte, Disturbances of blood lipids.The symptomatic adverse reactions produced by Mycophenolate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Alopecia, Diarrhea, Dyspnea, Insomnia, Pain, Cough, GI hemorrhage, GI disturbance, Alopecia, dizziness.
Indications
Mycophenolate is primarily indicated in conditions like Graft rejection, Pophylaxis of acute renal transplant rejection, Pophylaxis of cardiac transplant rejection, Pophylaxis of hepatic transplant rejection, Symptoms associated with carcinoid tumours.
Interactions
Mycophenolate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCholestyramineConcurrent use decrease the AUC approximately 40%.Magnesium Oxides and HydroxidesConcurrent use decrease the absorption of mycophenolate.RifampicinSevelamer HClReduced level of mycophenolate is observed when co-administered with sevelamer HCl close monitoring of blood concentrations should be considered during the use of combination and after its withdrawal. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Complete blood cell count
Risks
Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
It should be used with care in patients with severe renal impairment or active disorders of gastrointestinal tract. Therapy should begin as soon as possible after transplantation. Patient should undergo regular blood counts. If neutropenia develops than therapy should be stop or reducing the dose.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.